Nls Pharmaceutics Ag Stock Buy Hold or Sell Recommendation
| NLSP Stock | USD 1.58 0.05 3.27% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding NLS Pharmaceutics AG is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell NLS Pharmaceutics AG within the specified time frame.
Check out NLS Pharmaceutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as NLS and provide practical buy, sell, or hold advice based on investors' constraints. NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
NLS |
Execute NLS Pharmaceutics Buy or Sell Advice
The NLS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on NLS Pharmaceutics AG. Macroaxis does not own or have any residual interests in NLS Pharmaceutics AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute NLS Pharmaceutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
NLS Pharmaceutics Trading Alerts and Improvement Suggestions
| NLS Pharmaceutics had very high historical volatility over the last 90 days | |
| NLS Pharmaceutics may become a speculative penny stock | |
| NLS Pharmaceutics has a very high chance of going through financial distress in the upcoming years | |
| NLS Pharmaceutics AG currently holds 1.63 M in liabilities. NLS Pharmaceutics has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about NLS Pharmaceutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (12.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NLS Pharmaceutics AG currently holds about 1.35 M in cash with (9.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| NLS Pharmaceutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: NLSP stock touches 52-week low at 1.71 amid steep annual decline - Investing.com India |
NLS Pharmaceutics Returns Distribution Density
The distribution of NLS Pharmaceutics' historical returns is an attempt to chart the uncertainty of NLS Pharmaceutics' future price movements. The chart of the probability distribution of NLS Pharmaceutics daily returns describes the distribution of returns around its average expected value. We use NLS Pharmaceutics AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of NLS Pharmaceutics returns is essential to provide solid investment advice for NLS Pharmaceutics.
| Mean Return | -0.0092 | Value At Risk | -10.78 | Potential Upside | 19.00 | Standard Deviation | 10.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of NLS Pharmaceutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
NLS Stock Institutional Investors
The NLS Pharmaceutics' institutional investors refer to entities that pool money to purchase NLS Pharmaceutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Bvf Inc | 2024-12-31 | 143.7 K | Ubs Group Ag | 2024-12-31 | 8.3 K | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Bank Of America Corp | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Hrt Financial Llc | 2024-09-30 | 0.0 |
NLS Pharmaceutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 41.1K | 0.0 | 13.5K | 21.8K | 25.1K | 16.8K | |
| Change In Cash | (126.6K) | 5.3M | 3.5M | (8.1M) | (7.2M) | (6.9M) | |
| Net Borrowings | 557.9K | 667.7K | 1.2M | (2.1M) | (1.9M) | (1.8M) | |
| Free Cash Flow | (729.4K) | (15.0M) | (13.9M) | (9.7M) | (8.7M) | (9.2M) | |
| Other Non Cash Items | (72.1M) | 166.5K | 364.6K | 59.5K | 53.6K | 56.3K | |
| Net Income | (2.9M) | (11.9M) | (16.5M) | (12.2M) | (11.0M) | (11.5M) | |
| End Period Cash Flow | 93.7K | 5.4M | 8.9M | 897.7K | 1.0M | 980.7K | |
| Change To Netincome | 655.8K | 385.0K | (4.3K) | 124.9K | 112.4K | 201.1K |
NLS Pharmaceutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to NLS Pharmaceutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that NLS Pharmaceutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a NLS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.02 | |
β | Beta against Dow Jones | 0.38 | |
σ | Overall volatility | 10.85 | |
Ir | Information ratio | 0.01 |
NLS Pharmaceutics Volatility Alert
NLS Pharmaceutics AG is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure NLS Pharmaceutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact NLS Pharmaceutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.NLS Pharmaceutics Fundamentals Vs Peers
Comparing NLS Pharmaceutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NLS Pharmaceutics' direct or indirect competition across all of the common fundamentals between NLS Pharmaceutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NLS Pharmaceutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NLS Pharmaceutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NLS Pharmaceutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NLS Pharmaceutics to competition |
| Fundamentals | NLS Pharmaceutics | Peer Average |
| Return On Equity | -8.63 | -0.31 |
| Return On Asset | -2.28 | -0.14 |
| Current Valuation | 7.57 M | 16.62 B |
| Shares Outstanding | 4.06 M | 571.82 M |
| Shares Owned By Insiders | 40.85 % | 10.09 % |
| Shares Owned By Institutions | 17.37 % | 39.21 % |
| Number Of Shares Shorted | 169.51 K | 4.71 M |
| Price To Book | 4.84 X | 9.51 X |
| EBITDA | (11.8 M) | 3.9 B |
| Net Income | (12.17 M) | 570.98 M |
| Cash And Equivalents | 1.35 M | 2.7 B |
| Cash Per Share | 0.08 X | 5.01 X |
| Total Debt | 1.63 M | 5.32 B |
| Current Ratio | 0.59 X | 2.16 X |
| Book Value Per Share | (9.40) X | 1.93 K |
| Cash Flow From Operations | (9.68 M) | 971.22 M |
| Short Ratio | 0.01 X | 4.00 X |
| Earnings Per Share | (6.74) X | 3.12 X |
| Target Price | 6.0 | |
| Beta | -0.3 | -0.15 |
| Market Capitalization | 6.41 M | 19.03 B |
| Total Asset | 1.85 M | 29.47 B |
| Retained Earnings | (70.37 M) | 9.33 B |
| Working Capital | (6.1 M) | 1.48 B |
| Net Asset | 1.85 M |
NLS Pharmaceutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as NLS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About NLS Pharmaceutics Buy or Sell Advice
When is the right time to buy or sell NLS Pharmaceutics AG? Buying financial instruments such as NLS Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having NLS Pharmaceutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.